Assyro AI

Orange Book product · Brand (NDA)

DOXIL (LIPOSOMAL)

DOXORUBICIN HYDROCHLORIDE

Brand (NDA)NDA 050718TE ABRX BAXTER HLTHCARE CORP

At a glance

Nov 17, 1995

Approved

Brand (NDA)

Application

AB

TE code

None

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Nov 17, 1995

    31 yr ago

  2. Today

Pharmaceutical detail

Active ingredient

DOXORUBICIN HYDROCHLORIDE

Strength

20MG/10ML (2MG/ML)

Dosage form

INJECTABLE, LIPOSOMAL

Route

INJECTION

TE code

AB

Application

NDA 050718

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.